drugset / Trial / NCT04483297
First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS)
Phase 1
Terminated
30 enrolled
Asahi Kasei Therapeutics Corporation
Emergent Clinical Consulting, LLC · collab
RandomizedSequentialOpen-labelTreatment
Summary
The safety and efficacy of AK1320 MS will be evaluated in patients with degenerative spondylolisthesis and concomitant symptomatic spinal stenosis who are undergoing decompression and single level instrumented posterolateral lumber autograft fusion surgery.
Timeline
- Start
- 2020-11-18
- Primary completion
- 2023-11-27
- Completion
- 2024-01-30
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK1320 MS | Unknown | — | — |